remicade

Tylenol and Band-Aid maker Johnson & Johnson announced on Tuesday that its sales declined 0.7% to $15 billion in the third quarter, compared to the same quarter last year, as domestic sales were "significantly impacted" by recent successive recalls. Domestic sales declined 2.5%.

Abbott Laboratories (ABT) probably did not want to be the one to break this particular record, but it wasn't up to the big pharmaceutical company. It was up to a jury, and the jury ordered Abbott to pay Johnson & Johnson (JNJ) $1.67 billion for patent infringement of its rheumatoid arthritis...